Literature DB >> 9498303

Matrix metalloproteinases and diseases of the CNS.

V W Yong1, C A Krekoski, P A Forsyth, R Bell, D R Edwards.   

Abstract

Matrix metalloproteinases (MMPs) are increasingly being implicated in the pathogenesis of several CNS diseases. In multiple sclerosis, MMPs could be responsible for the influx of inflammatory mononuclear cells into the CNS, contribute to myelin destruction and disrupt the integrity of the blood-brain barrier; in Alzheimer's disease, MMPs might mediate the deposition of amyloid beta-proteins; and MMPs are known to contribute to the invasiveness of malignant glioma cells and might regulate their angiogenic capacity. Nonetheless, MMPs could also have beneficial roles in recovery from CNS injury.Therefore, both the identity of the MMP and its cellular origin could determine whether disease pathogenesis or regeneration occurs, and thus synthetic MMP inhibitors might be valuable for treating some CNS diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9498303     DOI: 10.1016/s0166-2236(97)01169-7

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  134 in total

Review 1.  Extracellular matrix degradation by metalloproteinases and central nervous system diseases.

Authors:  A Lukes; S Mun-Bryce; M Lukes; G A Rosenberg
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

Review 2.  The role of TNFalpha and lymphotoxin in demyelinating disease.

Authors:  C Lock; J Oksenberg; L Steinman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

3.  Matrix metalloproteinase-9 and -2 expression in the olfactory bulb following methyl bromide gas exposure.

Authors:  Stephen R Bakos; James E Schwob; Richard M Costanzo
Journal:  Chem Senses       Date:  2010-06-07       Impact factor: 3.160

4.  Gene expression profiles of the rat cochlea, cochlear nucleus, and inferior colliculus.

Authors:  Younsook Cho; Tzy-Wen L Gong; Timo Stöver; Margaret I Lomax; Richard A Altschuler
Journal:  J Assoc Res Otolaryngol       Date:  2002-03

5.  Complementary and alternative medicine for the treatment of multiple sclerosis.

Authors:  Vijayshree Yadav; Lynne Shinto; Dennis Bourdette
Journal:  Expert Rev Clin Immunol       Date:  2010-05       Impact factor: 4.473

6.  Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis.

Authors:  S L Leib; D Leppert; J Clements; M G Täuber
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

7.  IL-1β Induces MMP-9-Dependent Brain Astrocytic Migration via Transactivation of PDGF Receptor/NADPH Oxidase 2-Derived Reactive Oxygen Species Signals.

Authors:  Chuen-Mao Yang; Hsi-Lung Hsieh; Ping-Hsien Yu; Chih-Chung Lin; Shiau-Wen Liu
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

8.  Urokinase-type plasminogen activator induces BV-2 microglial cell migration through activation of matrix metalloproteinase-9.

Authors:  Sun Mi Shin; Kyu Suk Cho; Min Sik Choi; Sung Hoon Lee; Seol-Heui Han; Young-Sun Kang; Hee Jin Kim; Jae Hoon Cheong; Chan Young Shin; Kwang Ho Ko
Journal:  Neurochem Res       Date:  2010-02-23       Impact factor: 3.996

9.  CCAAT/enhancer binding protein β expression is increased in the brain during HIV-1-infection and contributes to regulation of astrocyte tissue inhibitor of metalloproteinase-1.

Authors:  Jerel Fields; Jessica Gardner-Mercer; Kathleen Borgmann; Ian Clark; Anuja Ghorpade
Journal:  J Neurochem       Date:  2011-03-14       Impact factor: 5.372

10.  Suppression of matrix metalloproteinase activity by SI-27: detection by a new activity assay with S-2444, a specific chromogenic peptide.

Authors:  Daizo Yoshida; Kunihiro Watanabe; Masahiro Noha; Hiroshi Takahashi; Akira Teramoto
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.